About: Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 2007 (uk) article scientifique publié en 2007 (fr) im Dezember 2007 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q57753793-66732648-5B12-435D-9BA0-EE4011835E60
publication date	2007-12-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q57753793-36CCEDE6-05AC-4E86-96DE-CEF570AA309B
cites work	Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
author name string	wds:Q57753793-0AC2A21B-34ED-423C-9730-24E955E7AF3C wds:Q57753793-23E8EA59-5ECC-4343-AB40-34FB1B3599C0 wds:Q57753793-69AD17FE-3A2A-4F0C-804E-5A2E68FC69B2 wds:Q57753793-7D7807F7-3131-4881-A927-3145FEB6D3E8 wds:Q57753793-805CAE15-CBFA-4BD5-986C-F406ED727E1F wds:Q57753793-894F3FB5-6DEF-42AE-A7DC-E7AECC8D44B2 wds:Q57753793-91F68CD0-9951-46ED-AE0F-E8BCA1E3B3F9 wds:Q57753793-9653D445-517D-47F9-AE86-140ABE7064B6 wds:Q57753793-AADB9DD4-8A86-4F2E-B2E1-7415519218C1 wds:Q57753793-C03AD3C7-A372-4610-9397-00180242FB43 wds:Q57753793-C34D92D2-9E37-4345-BAB5-178D66FD7FBD
author name string	Edward Keystone Fabio Magrini Roy Fleischmann Simon Cooper Sunil Agarwal Joan Bathon Daniel E. Furst James Udell Andrew Baldassare Andrew Chubick Matthew W. Cravets
rdfs:label	Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis (en) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis (nl)
skos:prefLabel	Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis (en) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis (nl)
name	Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis (en) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis (nl)
author	wds:Q57753793-A2FF5990-874A-4D58-BC9E-15239CDF7AB0 wds:Q57753793-D999C3FD-588C-40C9-B25F-7979654A4FFC wds:Q57753793-F12B0244-E6D6-4901-A845-02D1F3F3DA48 wds:Q57753793-F43E768F-A59E-43F0-9920-8FDCB0C4BC32
author	Ronald van Vollenhoven Maxime Dougados Paul Emery Gianfranco Ferraccioli
title	wds:Q57753793-3FFFC6D1-6EB7-40AB-A3FA-72BE402A482B
title	Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis (en)
page(s)	wds:Q57753793-6C2DF23C-109A-4117-998C-7F553EC60205
page(s)	3896-3908
instance of	wds:Q57753793-FAB3E4CC-B409-4E19-A09E-01CD9DD2294E
instance of	scholarly article
main subject	wds:Q57753793-08851B5C-74F9-4D46-9D15-75793CBB418B wds:Q57753793-2179DCA4-063C-4A55-9C2B-43BEE767C843 wds:Q57753793-8AF6EA0B-3D77-426C-A23A-8731B81C5C37 wds:Q57753793-E6AEABD3-1730-4ECA-8990-3318FD465A00 wds:Q57753793-F0C06DAE-19D8-40D8-9D5C-C214C6D005E0
main subject	rheumatoid arthritis rheumatology Patients rituximab immunology
PubMed ID	wds:Q57753793-64874B6E-99FC-4D98-88A3-26A83B675BA7
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18050221
PubMed ID	18050221
published in	wds:Q57753793-090F58FF-7AE0-4F1D-842C-95CC27EA53E7
published in	Arthritis and Rheumatism
issue	wds:Q57753793-AF1DE67D-07FE-4763-AA16-238CE832CF8B
volume	wds:Q57753793-5AB98E90-EFEA-4BA5-8CB3-4202D5AAC2D8
issue	12
volume	56
DOI	wds:Q57753793-4E5B69BE-6A5E-473F-BEBD-A2A4C56DA4BB
DOI	http://dx.doi.org/10.1002/ART.23059
DOI	10.1002/ART.23059
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57753793
is cites work of	Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis Rheumatoid arthritis Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience Rituximab in autoimmune diseases To switch or to change class-the biologic dilemma in rheumatoid arthritis. Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland Good and bad memories following rituximab therapy Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks? Adverse effects of biologics: a network meta-analysis and Cochrane overview Recent advances in the genetics of autoimmune disease B cells in the pathogenesis and treatment of rheumatoid arthritis Assessing infection risk with biologic agents in RA: methodological challenges Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab' Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR) The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis Infectious complications associated with monoclonal antibodies and related small molecules Treatment of rheumatoid arthritis: state of the art 2009. Indications of rituximab in autoimmune diseases

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software